AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

North America Travel Vaccines Market Expected to Generate a Value of US $3.3 Billion During the Period, 2019-2024 - ResearchAndMarkets.com

January 8, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 8, 2020--

The “North America Travel Vaccines Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering.

The publisher expects the market to reach a value of US$ 3.3 Billion by 2024, registering a CAGR of 5.3% during 2019-2024.

The North America travel vaccines market reached a value of US$ 2.4 Billion in 2018. Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.

North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.

Key Questions Answered in This Report:

Report Coverage:

Key Topics Covered:

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Travel Vaccines Market

5.1 Market Performance

5.2 Market Breakup by Composition

5.3 Market Breakup by Disease

5.4 Market Breakup by Region

5.5 Market Forecast

6 North America Travel Vaccines Market

6.1 Market Performance

6.2 Market Forecast

7 North America Travel Vaccines Market: Breakup by Composition

7.1 Mono Vaccines

7.2 Combination Vaccines

8 North America Travel Vaccines Market: Breakup by Disease

8.1 Hepatitis A

8.2 DPT

8.3 Yellow Fever

8.4 Typhoid

8.5 Hepatitis B

8.6 Measles and Mumps

8.7 Rabies

8.8 Meningococcal

8.9 Varicella

8.10 Japanese Encephalitis

8.11 Others

9 North America Travel Vaccines Market: Breakup by Country

9.1 United States

9.1.1 Historical market Trends

9.1.2 Market Breakup by Composition

9.1.3 Market Breakup by Disease

9.1.4 Market Forecast

9.2 Canada

9.3 Mexico

10 SWOT Analysis

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 Value Chain Analysis

11.1 Overview

11.2 Exploratory Stage

11.3 Preclinical and Clinical Development

11.4 Regulatory Approval

11.5 Manufacturing

11.6 Marketing and Distribution

12 Porter’s Five Forces Analysis

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Rivalry

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/7tnjmu

View source version on businesswire.com:https://www.businesswire.com/news/home/20200108005608/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/08/2020 10:34 AM/DISC: 01/08/2020 10:34 AM

http://www.businesswire.com/news/home/20200108005608/en